Advanced

A generic model for C-11 labelled radiopharmaceuticals for imaging receptors in the human brain

Nosslin, Bertil LU ; Johansson, L; Leide Svegborn, Sigrid LU ; Liniecki, J; Mattsson, Sören LU and Taylor, DM (2003) In Radiation Protection Dosimetry 105(1-4). p.587-591
Abstract
A large number of rachopharmaceuticals labelled with C-11 (half-time 0.340 h) are being developed for positron emission tomographic studies of different types of receptor in the human brain. For most of these agents, the available biokinetic data are insufficient to construct realistic compound-specific biokinetic models for calculating the internal radiation dose delivered to persons undergoing investigation. A generic model for brain receptor substances that predicts the internal dose with sufficient accuracy for general radiation protection purposes has, therefore, been developed. Biokinetic data for 13 C-11-radiopharmaceuticals used clinically for imaging different brain receptors indicate that, despite differences in chemical... (More)
A large number of rachopharmaceuticals labelled with C-11 (half-time 0.340 h) are being developed for positron emission tomographic studies of different types of receptor in the human brain. For most of these agents, the available biokinetic data are insufficient to construct realistic compound-specific biokinetic models for calculating the internal radiation dose delivered to persons undergoing investigation. A generic model for brain receptor substances that predicts the internal dose with sufficient accuracy for general radiation protection purposes has, therefore, been developed. Biokinetic data for 13 C-11-radiopharmaceuticals used clinically for imaging different brain receptors indicate that, despite differences in chemical structure. their uptake and retention in the human brain and other tissues are broadly similar. The proposed model assumes instantaneous deposition of 5% of the injected radioactivity in the brain, with the remaining radioactivity being rapidly and uniformly distributed throughout all other tissues. Elimination from all tissues is assumed to occur with a half-time of 2 h. It is further assumed that 75% of the injected C-11 is excreted in the urine, and 25% via the gall bladder, with a half-time of 2 h. This model yields all effective dose of 4.5 X 10(-3) mSv MBq(-1), with doses of 3.2 X 10(-2), 1.7 X 10(-2), 8.7 X 10(-3), 5.2 X 10(-3), and 3.8 X 10(-3) mGy MBq(-1) to the urinary bladder, gall bladder, kidneys, brain and ovaries, respectively. These closes are well within the range of those reported using compound-specific models for the radiopharmaceutals studied. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Radiation Protection Dosimetry
volume
105
issue
1-4
pages
587 - 591
publisher
Nuclear Technology Publishing
external identifiers
  • wos:000185533200116
  • pmid:14527032
ISSN
1742-3406
language
English
LU publication?
yes
id
1e149c60-c34d-45d2-b10e-dfdb6bc9cf32 (old id 299661)
date added to LUP
2007-08-03 14:22:57
date last changed
2016-04-16 05:10:18
@article{1e149c60-c34d-45d2-b10e-dfdb6bc9cf32,
  abstract     = {A large number of rachopharmaceuticals labelled with C-11 (half-time 0.340 h) are being developed for positron emission tomographic studies of different types of receptor in the human brain. For most of these agents, the available biokinetic data are insufficient to construct realistic compound-specific biokinetic models for calculating the internal radiation dose delivered to persons undergoing investigation. A generic model for brain receptor substances that predicts the internal dose with sufficient accuracy for general radiation protection purposes has, therefore, been developed. Biokinetic data for 13 C-11-radiopharmaceuticals used clinically for imaging different brain receptors indicate that, despite differences in chemical structure. their uptake and retention in the human brain and other tissues are broadly similar. The proposed model assumes instantaneous deposition of 5% of the injected radioactivity in the brain, with the remaining radioactivity being rapidly and uniformly distributed throughout all other tissues. Elimination from all tissues is assumed to occur with a half-time of 2 h. It is further assumed that 75% of the injected C-11 is excreted in the urine, and 25% via the gall bladder, with a half-time of 2 h. This model yields all effective dose of 4.5 X 10(-3) mSv MBq(-1), with doses of 3.2 X 10(-2), 1.7 X 10(-2), 8.7 X 10(-3), 5.2 X 10(-3), and 3.8 X 10(-3) mGy MBq(-1) to the urinary bladder, gall bladder, kidneys, brain and ovaries, respectively. These closes are well within the range of those reported using compound-specific models for the radiopharmaceutals studied.},
  author       = {Nosslin, Bertil and Johansson, L and Leide Svegborn, Sigrid and Liniecki, J and Mattsson, Sören and Taylor, DM},
  issn         = {1742-3406},
  language     = {eng},
  number       = {1-4},
  pages        = {587--591},
  publisher    = {Nuclear Technology Publishing},
  series       = {Radiation Protection Dosimetry},
  title        = {A generic model for C-11 labelled radiopharmaceuticals for imaging receptors in the human brain},
  volume       = {105},
  year         = {2003},
}